ONCOPEPTIDES ABONCOPEPTIDES ABONCOPEPTIDES AB

ONCOPEPTIDES AB

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
Revenue estimate
Market capitalization
‪57.00 M‬USD
−0.1940USD
‪−24.59 M‬USD
‪3.48 M‬USD
‪129.58 M‬
Beta (1Y)
0.03

About ONCOPEPTIDES AB

CEO
Sofia Heigis
Headquarters
Stockholm
Employees (FY)
57
Founded
2000
ISIN
SE0009414576
FIGI
BBG00YHLZ4X7
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ONPPF is 0.6000 USD — it has decreased by 29.41% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange ONCOPEPTIDES AB stocks are traded under the ticker ONPPF.
ONCOPEPTIDES AB is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
ONPPF stock is 41.67% volatile and has beta coefficient of 0.03. Check out the list of the most volatile stocks — is ONCOPEPTIDES AB there?
ONPPF earnings for the last quarter are −0.04 USD per share, whereas the estimation was −0.06 USD resulting in a 34.74% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about ONCOPEPTIDES AB earnings.
ONCOPEPTIDES AB revenue for the last quarter amounts to ‪2.40 M‬ USD despite the estimated figure of ‪2.33 M‬ USD. In the next quarter revenue is expected to reach ‪2.50 M‬ USD.
Yes, you can track ONCOPEPTIDES AB financials in yearly and quarterly reports right on TradingView.
ONPPF net income for the last quarter is ‪−8.02 M‬ USD, while the quarter before that showed ‪−3.70 M‬ USD of net income which accounts for −116.78% change. Track more ONCOPEPTIDES AB financial stats to get the full picture.
Today ONCOPEPTIDES AB has the market capitalization of ‪55.87 M‬, it has decreased by 0.59% over the last week.
No, ONPPF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ONPPF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOPEPTIDES AB stock right from TradingView charts — choose your broker and connect to your account.
ONPPF reached its all-time high on Dec 16, 2020 with the price of 20.3800 USD, and its all-time low was 0.4500 USD and was reached on Oct 25, 2021.
See other stocks reaching their highest and lowest prices.
As of Apr 29, 2024, the company has 57.00 employees. See our rating of the largest employees — is ONCOPEPTIDES AB on this list?
We've gathered analysts' opinions on ONCOPEPTIDES AB future price: according to them, ONPPF price has a max estimate of 0.92 USD and a min estimate of 0.36 USD. Read a more detailed ONCOPEPTIDES AB forecast: see what analysts think of ONCOPEPTIDES AB and suggest that you do with its stocks.